Skip to main content

Advertisement

SpringerLink
Log in

Utilizing Quality by Design to Develop and Evaluate Extended-Release Upadacitinib Tablets Incorporating a Biosynthesized Polymer

  • Original Article
  • Published:
Journal of Pharmaceutical Innovation Aims and scope Submit manuscript

Abstract

Objectives

The aim of this study was to develop and optimize the production of upadacitinib extended-release tablets containing biosynthesized hydrophilic carriers and/or polymers in the core and coating. This was achieved by applying quality by design (QbD) approach and its built-in quality control aspects to adhere to the general principles of sustainability including subsistence, efficiency, and consistency during the product life cycle. Upadacitinib is an inhibitor of the Janus kinase class of enzymes. In this study, the characterization of the reference product, physicochemical parameters of the drug molecule, and the quality target product profile was considered along with critical attributes of quality to initiate drug development. Critical attributes related to material properties, process parameters, and the formulation variables were identified, and their preliminary level of risk was assessed. The factorial design of an experiment with three center points was achieved using Design Expert v12 to investigate the customary monolithic extended-release tablets of matrix formulation. In order to evaluate tablet performance, critical quality attributes (CQAs) were determined by dissolution tests. Finally, factors that can influence the formulation, including its compositions, manufacturing procedures, and analytical evaluation, were examined. The goal was to identify formulations that exhibit a similar release pattern through the entire 12-h dissolution testing period.

Materials and Methods

Various release rates of biosynthesized polymer-based upadacitinib extended-release formulations were compared to the reference product, Innovator (Rinvoq), using in vitro dissolution test. The selected “T-5” formulation was optimized and evaluated using the QbD method to satisfy the principles of sustainability throughout the product life cycle.

Results

All experimental upadacitinib tablet formulations demonstrated favorable drug release patterns, though not to the required extent. However, the “T-5” formulation released 80% of the drug within the required time.

Conclusions

The “T-5” formulation was considered suitable for the further development of extended-release tablets of upadacitinib, as it contained optimal amount of biosynthesized hydrophilic polymer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Nair AK, Ramana PV, Rao PVB, Reddy BH, Ganthi HKR, Mallu UR. Carobomer based controlled release designs of atorvastatin calcium tablets evaluated using quality by design (QbD) approach. Am J Anal Chem. 2017;8:189–209. https://doi.org/10.4236/ajac.2017.83016.

    Article  CAS  Google Scholar 

  2. Mamatha T, Koneru A, Hadi MA, Qureshi HK. Formulation and evaluation of extended-release tablets of an antidepressant drug venlafaxine HCL. Int J Res Pharm Sci. 2018;9(4):1146–1153. https://doi.org/10.26452/ijrps.v9i4.1647.

  3. Sloneker JH, Orentas DG. Nature. 1962;194:478–9.

    Article  PubMed  CAS  Google Scholar 

  4. Sloneker JH, Orentas DG, Jeanes A. Can J Chem. 1964;42:1261–9.

    Article  CAS  Google Scholar 

  5. Jeanes A, Pittsley J, Senti FR. Polysaccharide B-1459: A new hydrocolloid polyelectrolyte produced from glucose by bacterial fermentation. Chem- J Appl Poly Sci.1961.

  6. Leela JK, Sharma G. Studies on xanthan production from Xanthomonas campestris. Bioprocess Eng. 2000;23(6):687–9.

    Article  Google Scholar 

  7. Varshosaz J, Tavakoli N, Kheirolahi F. Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride. AAPS PharmSciTech 2006;7(1) Article 24.

  8. Andreopoulos AG, Tarantili PA. Xanthan gum as a carrier for controlled release of drugs. J Biomater Appl. 2001;16(1):34–46.

    Article  PubMed  CAS  Google Scholar 

  9. Vendruscolo CW, Andreazza IF, Ganter Ferrero JLC, Bresolin TM, Xanthan and galactomannan (from M. scabrella) matrix tablets for oral controlled delivery of theophylline. Int J Pharm. 2005; 296(1–2):1–11.

  10. Talukdar MM, Rombaut P, Kinget R. The release mechanism of an oral controlled - release delivery system for indomethacin. Pharm Dev Technol. 1998;3(1):1–6.

    Article  PubMed  CAS  Google Scholar 

  11. Yeole PG, Galgatte UC, Babla IB, Nakhat PD. Design and evaluation of xanthan gum-based sustained release matrix tablets of diclofenac sodium. Indian J Pharm Sci. 2006;68(2):185–9.

    Article  CAS  Google Scholar 

  12. Rinvoq Pill. (upadacitinib) extended-release tablets, for oral use (Initial U.S. Approval: 2019) prescribing information leaflet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095. Revised 04/2022.

  13. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–87.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs in Context. 2019;8:212–595. https://doi.org/10.7573/dic.212595.

    Article  Google Scholar 

  15. Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30(5):779–87. https://doi.org/10.1080/14397595.2020.1782049.

    Article  PubMed  CAS  Google Scholar 

  16. Avci AB, Feist E, Burmester GR. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis. Rheumatology 2021;60:ii11-ii16. https://doi.org/10.1093/rheumatology/keaa893.

  17. Sandborn WJ, Feagan BG, Loftus EV Jr. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020;158(8):2123-2138.e8. https://doi.org/10.1053/j.gastro.2020.01.047.

    Article  PubMed  CAS  Google Scholar 

  18. Guttman-Yassky E, Thaci D, Pangan AL. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–84. https://doi.org/10.1016/j.jaci.2019.11.025.

    Article  PubMed  CAS  Google Scholar 

  19. Patel H, Parmar S, Patel B. A comprehensive review on quality by design (QbD) in pharmaceuticals. Int J Pharm Sci Rev Res. 2013;21(1):223–36.

    Google Scholar 

  20. Nadpara NP, Thumar RV, Kolala VN, Patel PB. “Quality by design (QbD): a complete review. Int J Pharm Sci Rev Res. 2012;17(2):20–8.

    Google Scholar 

  21. Sanjay B, Sarwar B, Babita G, Abhay A, Gyati S. Asthana, Bhupinder S. QbD oriented development and characterization of effervescent floating bioadhesive tablets of cefuroxime axetil. AAPS Pharm Sci Tech. 2016;17:1086–99. https://doi.org/10.1208/s12249-015-0431-9.

    Article  CAS  Google Scholar 

  22. Ajinkya U, Sanjay K, Mangesh B. Design and optimization of sustained release matrix tablet of opipramol HCL by using quality by design approach”. Asian J Pharm Clin Res. 2014;7:227–34.

    Google Scholar 

  23. Jc A, Gaurav C, Francesco G. Designing the design of experiments (DOE) – an investigation on the influence of different factorial designs on the characterization of complex systems. Energy & buildings. 2011;250:111298.

    Google Scholar 

  24. Klünder B, Mittapalli RK, Mohamed MF, Friedel A, Noertersheuser P, Othman AA. Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019;58(8):1045–58. https://doi.org/10.1007/s40262-019-00739-3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Mohamed MF, Jungerwirth S, Asatryan A, Jiang P, Othman AA. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br J Clin Pharmacol. 2017;83(10):2242–8. https://doi.org/10.1111/bcp.13329.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Pharmacopeia US. USP chapter< 616> bulk density and tapped density. Rockville: United States Pharmacopeia (USP 43–NF 38). 2020;2638.

Download references

Acknowledgements

We acknowledge the gift sample of raw material provider (Aurobindo Pharma Ltd., India) and facilitators (SAS, VIT University, Vellore India).

Author information

Authors and Affiliations

  1. School of Advanced Sciences, VIT University, Vellore, 632014, India

    K. Sunil Chowdary

  2. Pharmaceutical Chemistry Division, School of Advanced Sciences, VIT University, Vellore, 632014, India

    A. A. Napoleon

Authors
  1. K. Sunil Chowdary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. A. Napoleon
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Planning, methodology, investigation, writing, drafting, and editing: Sunil Chowdary. K. Supervision, review, and editing: Dr. A.A. Napoleon.

Corresponding author

Correspondence to A. A. Napoleon.

Ethics declarations

Ethics Approval

Not applicable.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sunil Chowdary, K., Napoleon, A. Utilizing Quality by Design to Develop and Evaluate Extended-Release Upadacitinib Tablets Incorporating a Biosynthesized Polymer. J Pharm Innov 18, 1879–1891 (2023). https://doi.org/10.1007/s12247-023-09754-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12247-023-09754-1

Keywords

Search

Navigation